Stock ScreenerStock IdeasHigh Risk, High RewardHigh Risk, High Reward StocksSpeculative companies with the highest upside potential according to WallStreet analysts. Proceed with extreme caution!
Stock ScreenerStock IdeasHigh Risk, High Reward
Consensus: Strong Buy + 1 more
Analysts: >= 2
Upside/Downside: >= 500%
| Ticker | Company | Zen Rating | Growth | Market Cap | Revenue | EBITDA | Earnings | EPS | Rev. Y/Y | Rev. 5Y | Earn. Y/Y | Earn. 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FBLG | FIBROBIOLOGICS INC | $22.62M | $0.00 | -$12.55M | -$13.22M | -$0.36 | N/A | N/A | N/A | N/A | 2025-11-18 | ||
| KALA | KALA BIO INC | $9.94M | $0.00 | -$29.63M | -$35.65M | -$7.97 | N/A | -100.00% | N/A | N/A | |||
| ACXP | ACURX PHARMACEUTICALS INC | $7.23M | $0.00 | -$10.00M | -$10.00M | -$10.69 | N/A | N/A | N/A | N/A | 2025-11-18 | ||
| ATYR | ATYR PHARMA INC | $63.19M | $0.00 | -$62.26M | -$63.41M | -$0.80 | -100.00% | -100.00% | N/A | N/A | |||
| MRSN | MERSANA THERAPEUTICS INC | $39.93M | $34.77M | -$65.59M | -$74.04M | -$14.62 | 16.14% | 83.02% | N/A | N/A | 2025-11-11 | ||
| FEMY | FEMASYS INC | $11.30M | $1.70M | -$18.54M | -$21.11M | -$0.91 | 61.97% | N/A | N/A | N/A | 2025-11-06 | ||
| GOVX | GEOVAX LABS INC | $14.07M | $0.00 | -$24.71M | -$24.81M | -$2.01 | N/A | -100.00% | N/A | N/A | |||
| UNCY | UNICYCIVE THERAPEUTICS INC | $81.60M | $0.00 | -$30.97M | -$31.56M | -$3.62 | N/A | N/A | N/A | N/A | |||
| RANI | RANI THERAPEUTICS HOLDINGS INC | $29.06M | $1.20M | -$22.18M | -$29.80M | -$0.99 | N/A | N/A | N/A | N/A | 2025-11-12 | ||
| FGEN | FIBROGEN INC | $48.24M | -$72.84M | $2.18M | -$2.07M | -$0.38 | N/A | N/A | N/A | N/A | |||
| NRXP | NRX PHARMACEUTICALS INC | $65.62M | $0.00 | -$33.79M | -$33.79M | -$2.24 | N/A | N/A | N/A | N/A | |||
| SGMO | SANGAMO THERAPEUTICS INC | $211.20M | $81.71M | -$55.42M | -$64.59M | -$0.29 | 565.52% | -6.02% | N/A | N/A | 2025-10-30 | ||
| PSTV | PLUS THERAPEUTICS INC | $67.70M | $5.32M | -$14.57M | -$19.03M | -$2.03 | -3.49% | -3.22% | N/A | N/A | |||
| GRI | GRI BIO INC | $4.96M | $0.00 | -$10.02M | -$11.92M | $3.81 | N/A | N/A | -99.72% | N/A | |||
| BTAI | BIOXCEL THERAPEUTICS INC | $38.43M | $868.00k | -$34.61M | -$50.95M | -$11.94 | -63.88% | N/A | N/A | N/A | |||
| BOLT | BOLT BIOTHERAPEUTICS INC | $9.52M | $4.17M | -$47.13M | -$50.71M | -$26.46 | -62.68% | N/A | N/A | N/A | |||
| ENLV | ENLIVEX THERAPEUTICS LTD | $24.81M | $0.00 | -$14.99M | -$13.10M | -$0.58 | N/A | N/A | N/A | N/A | 2025-12-01 | ||
| MDCX | MEDICUS PHARMA LTD | $44.72M | $0.00 | -$16.73M | -$16.51M | -$1.34 | N/A | N/A | N/A | N/A | 2025-11-21 | ||
| LSTA | LISATA THERAPEUTICS INC | $21.93M | $1.00M | -$20.10M | -$19.31M | -$2.30 | N/A | N/A | N/A | N/A | 2025-11-06 | ||
| MTVA | METAVIA INC | $23.76M | $0.00 | -$18.47M | -$18.49M | -$1.49 | N/A | N/A | N/A | N/A | |||
| KAPA | KAIROS PHARMA LTD | $23.86M | $0.00 | -$4.70M | -$4.71M | -$0.34 | N/A | N/A | N/A | N/A | |||
| CING | CINGULATE INC | $21.97M | $0.00 | -$17.32M | -$17.96M | -$4.10 | N/A | N/A | N/A | N/A | |||
| CRDL | CARDIOL THERAPEUTICS INC | $86.81M | $0.00 | -$27.19M | -$27.41M | -$0.34 | N/A | N/A | N/A | N/A | 2025-11-18 | ||
| MYO | MYOMO INC | $34.66M | $40.76M | -$7.41M | -$9.32M | -$0.22 | 93.07% | 59.13% | N/A | N/A | 2025-11-05 | ||
| CERO | CERO THERAPEUTICS HOLDINGS INC | $6.50M | $0.00 | -$12.97M | -$41.91M | -$66.53 | N/A | N/A | N/A | N/A | |||
| INTS | INTENSITY THERAPEUTICS INC | $12.71M | $0.00 | -$12.55M | -$12.58M | -$0.82 | N/A | N/A | N/A | N/A | 2025-11-18 | ||
| JSPR | JASPER THERAPEUTICS INC | $39.33M | $0.00 | -$88.84M | -$90.92M | -$6.03 | N/A | N/A | N/A | N/A | |||
| SLN | SILENCE THERAPEUTICS PLC | $245.37M | $27.37M | -$73.76M | -$79.40M | N/A | 21.64% | 73.57% | N/A | N/A | 2025-11-13 | ||
| IPSC | CENTURY THERAPEUTICS INC | $43.02M | $114.13M | -$7.37M | -$23.28M | -$0.29 | 5,489.03% | N/A | N/A | N/A | 2025-11-06 | ||
| MBRX | MOLECULIN BIOTECH INC | $15.14M | $0.00 | -$26.43M | -$26.55M | -$3.52 | N/A | N/A | N/A | N/A | |||
| NOTE | FISCALNOTE HOLDINGS INC | $71.32M | $109.68M | -$24.45M | -$45.84M | -$3.84 | -15.39% | N/A | N/A | N/A | 2025-11-18 | ||
| PMN | PROMIS NEUROSCIENCES INC | $24.25M | $0.00 | -$8.43M | -$8.43M | -$0.21 | N/A | N/A | N/A | N/A | 2025-11-12 | ||
| PASG | PASSAGE BIO INC | $25.59M | $0.00 | -$55.01M | -$56.86M | -$18.16 | N/A | N/A | N/A | N/A | 2025-11-18 | ||
| IMUX | IMMUNIC INC | $92.27M | $0.00 | -$96.19M | -$96.40M | -$0.95 | N/A | N/A | N/A | N/A | 2025-11-06 | ||
| TIL | INSTIL BIO INC | $118.48M | $0.00 | -$74.48M | -$84.51M | -$12.92 | N/A | N/A | N/A | N/A | |||
| SNSE | SENSEI BIOTHERAPEUTICS INC | $11.86M | $0.00 | -$24.46M | -$26.82M | -$21.31 | N/A | N/A | N/A | N/A | |||
| ACET | ADICET BIO INC | $68.48M | $0.00 | -$107.56M | -$117.32M | -$1.29 | N/A | N/A | N/A | N/A | 2025-11-05 | ||
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS INC | $33.19M | $0.00 | -$27.07M | -$27.11M | -$0.65 | N/A | N/A | N/A | N/A | 2025-11-17 | ||
| EKSO | EKSO BIONICS HOLDINGS INC | $13.89M | $14.65M | -$9.25M | -$11.09M | -$6.64 | -19.32% | 6.35% | N/A | N/A | |||
| ATOS | ATOSSA THERAPEUTICS INC | $118.84M | $0.00 | -$28.70M | -$28.72M | -$0.23 | N/A | N/A | N/A | N/A | 2025-11-17 | ||
| ALLO | ALLOGENE THERAPEUTICS INC | $286.23M | $0.00 | -$223.22M | -$236.91M | -$1.11 | -100.00% | N/A | N/A | N/A | 2025-10-30 | ||
| ANVS | ANNOVIS BIO INC | $43.45M | $0.00 | -$30.26M | -$30.26M | -$1.99 | N/A | N/A | N/A | N/A | 2025-11-05 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.